Aib substitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-23 and is reviewed periodically as new material appears.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
John Lilley states, "...neutron-induced fission generates extra neutrons which can induce further fissions in the next generation and so on in a chain reaction. The chain reaction is characterized by the neutron multiplication factor k, which is defined as the ratio of the number of neutrons in one generation to the number in the preceding generation. If, in a reactor, k is less than unity, the reactor is subcritical, the number of neutrons decreases and the chain reaction dies out. If k > 1, the reactor is supercritical and the chain reaction diverges. This is the situation in a fission bomb where growth is at an explosive rate. If k is exactly unity, the reactions proceed at a steady rate and the reactor is said to be critical. It is possible to achieve criticality in a reactor using natural uranium as fuel, provided that the neutrons have been efficiently moderated to thermal energies." Moderators include light water, heavy water, and graphite. According to John C. Lee, "For all nuclear reactors in operation and those under development, the nuclear fuel cycle is based on one of three fissile materials, 235U, 233U, and 239Pu, and the associated isotopic chains. For the current generation of LWRs, the enriched U contains 2.5~4.5 wt% of 235U, which is fabricated into UO2 fuel rods and loaded into fuel assemblies." Lee states, "One important comparison for the three major fissile nuclides, 235U, 233U, and 239Pu, is their breeding potential.
=== Sources === The seeds of Ricinus communis are commonly crushed to extract castor oil. As ricin is not oil-soluble, little is found in the extracted castor oil. The extracted oil is also heated to more than 80 °C (176 °F) to denature any ricin that may be present. The remaining spent crushed seeds, called variously the "cake", "oil cake", and "press cake", can contain up to 5% ricin. While the oil cake from coconut, peanuts, and sometimes cotton seeds can be used as cattle feed or fertilizer, the toxic nature of castor beans precludes their oil cake from being used as feed unless the ricin is first deactivated by autoclaving. Accidental ingestion of Ricinus communis cake intended for fertilizer has been reported to be responsible for fatal ricin poisoning in animals. Deaths from ingesting castor plant seeds are rare, partly because of their indigestible seed coat, and because some of the ricin is deactivated in the stomach. The pulp from eight beans is considered dangerous to an adult. Rauber and Heard have written that close examination of early 20th century case reports indicates that public and professional perceptions of ricin toxicity "do not accurately reflect the capabilities of modern medical management". Most acute poisoning episodes in humans are the result of oral ingestion of castor beans, 5–20 of which could prove fatal to an adult. Swallowing castor beans rarely proves to be fatal unless the bean is thoroughly chewed. The survival rate of castor bean ingestion is 98%. In 2013 a 37-year-old woman in the United States survived after ingesting 30 beans.
== Structure and reactivity == DBNPA is a halogenated cyanoacetamide compound, characterized by the presence of two bromine atoms at the 2,2-position of the carbon backbone. DBNPA contains a cyano (-CN) group and an amide (-CONH2) group attached to a three-carbon chain. The molecular formula is C3H2Br2N2O, with a molecular weight of 241.87 g/mol. DBNPA is highly reactive due to the two electron-withdrawing bromine atoms and a cyano (-CN) group attached to the central carbon backbone. These substituents form a very electron-deficient core, making it highly vulnerable to nucleophilic attacks. The cyano group increases the reactivity of the compound by stabilizing the electron deficiency while the amide (−CONH2) group affects its water solubility. The electron-deficient carbon adjacent to the bromine atoms plays a critical role in DBNPA’s biocidal properties, leading to the disruption of microbial cellular functions. Since DBNPA is a highly reactive molecule, it is prone to pH-dependent hydrolysis at neutral and alkaline conditions because of the weak carbon-bromide bonds. DBNPA is also susceptible to be broken down in reducing environments by stepwise debromination. Additionally, DBNPA is highly sensitive to ultraviolet (UV) exposure, which accelerates its degradation in aqueous environments. Due to its reactive nature, DBNPA must be stabilized in products to prevent premature degradation before application.
=== Groupings and organizations === Lucha Libre AAA Worldwide, a Mexican wrestling promotion Asian Athletics Association, the continental athletics authority in Asia Amateur Athletic Association of England, the Athletic Association in England Arkansas Activities Association, for high school sports Montreal AAA, an amateur athletic association Triple-A (baseball), a North American Minor League Baseball classification level Senior ice hockey § Senior AAA hockey leagues
1985–1987 – 1.1 L (1,071 cc) E1, 2 barrel, 8-valve, 55 PS (40 kW; 54 hp) / 59 lb⋅ft (80 N⋅m) 1985–1987 – 1.3 L (1,296 cc) E3, 2 barrel, 8-valve, 68 PS (50 kW; 67 hp) / 71 lb⋅ft (96 N⋅m) – 60 PS (44 kW; 59 hp) in some markets, 65 PS in Switzerland 1987–1989 – 1.3 L (1,323 cc) B3, 2 barrel, 8-valve, 66 PS (49 kW; 65 hp) / 74 lb⋅ft (100 N⋅m) 1987–1989 – 1.5 L (1,498 cc) B5, 2 barrel, 12-valve, 73 PS (54 kW; 72 hp) / 81 lb⋅ft (110 N⋅m) 1985–1989 – 1.6 L (1,597 cc) B6, 8-valve, 85 PS (63 kW; 84 hp) / 90 lb⋅ft (122 N⋅m) 1985–1989 – 1.6 L (1,597 cc) B6T, turbo, 16-valve, 140 PS (103 kW; 138 hp) / 138 lb⋅ft (187 N⋅m) 1988–1991 – 2.0 L (1,998 cc) FE-SOHC, EFi, 8-valve, 118 PS (87 kW; 116 hp) / 131 lb⋅ft (178 N⋅m) (South Africa only) 1991–1994 – 2.0 L (1,998 cc) FE-DOHC, EFi, 16-valve, 146 PS (107 kW; 144 hp) / 136 lb⋅ft (184 N⋅m) (South Africa only) 1986–199? – 1.7 L (1,720 cc) PN, diesel, 8-valve, 57 PS (42 kW; 56 hp)
Sources: en.wikipedia.org
Fukuyama congenital muscular dystrophy (FCMD) is a rare, autosomal recessive form of muscular dystrophy (weakness and breakdown of muscular tissue) mainly described in Japan but also identified in Turkish and Ashkenazi Jewish patients; fifteen cases were first described on 1960 by Dr. Yukio Fukuyama.FCMD mainly affects the brain, eyes, and muscles, in particular, the disorder affects development of the skeletal muscles leading to weakness and deformed appearances, and brain development is blunted affecting cognitive functioning as well as social skills. In 1995, the disorder was linked to mutations in a gene coding for the protein fukutin (the FCMD gene). Fukuyama congenital muscular dystrophy is the second most prevalent form of muscular dystrophy in Japan. One out of every 90 people in Japan is a heterozygous carrier.
=== Metric ounce === A metric ounce is an approximation of the imperial ounce, US dry ounce, or US fluid ounce. These three customary units vary. However, the metric ounce is usually taken as 25 or 30 ml (0.88 or 1.06 imp fl oz; 0.85 or 1.01 US fl oz) when volume is being measured, or in grams when mass is being measured. The US Food and Drug Administration (FDA) defines the "food labeling ounce" as 30.0 ml (1.06 imp fl oz; 1.01 US fl oz), slightly larger than the 29.6 ml (1.04 imp fl oz; 1.00 US fl oz) fluid ounce. Several Dutch units of measurement have been replaced with informal metric equivalents, including the ons or ounce. It originally meant 1⁄16 of a pound, or a little over 30 g (1.1 oz) depending on which definition of the pound was used, but was redefined as 100 g (3.5 oz) when the country metricated.
=== International action: Stockholm Convention === PFOA was proposed for listing under the Stockholm Convention on Persistent Organic Pollutants in 2015, and on May 10, 2019, PFOA, its salts, and PFOA-related compounds were added to Annex A of the Stockholm Convention by the Conference of the Parties. Several hundred salts and precursors of PFOA fall within the scope of the restriction. A few specific exemptions remained. Among them is a time-bound exemption for PFOA in fire-fighting foam.
Nucleic acids consist of a chain of linked units called nucleotides. Each nucleotide consists of three subunits: a phosphate group and a sugar (ribose in the case of RNA, deoxyribose in DNA) make up the backbone of the nucleic acid strand, and attached to the sugar is one of a set of nucleobases. The nucleobases are important in base pairing of strands to form higher-level secondary and tertiary structures such as the famed double helix. The possible letters are A, C, G, and T, representing the four nucleotide bases of a DNA strand – adenine, cytosine, guanine, thymine – covalently linked to a phosphodiester backbone. In the typical case, the sequences are printed abutting one another without gaps, as in the sequence AAAGTCTGAC, read left to right in the 5' to 3' direction. With regards to transcription, a sequence is on the coding strand if it has the same order as the transcribed RNA. One sequence can be complementary to another sequence, meaning that they have the base on each position in the complementary (i.e., A to T, C to G) and in the reverse order. For example, the complementary sequence to TTAC is GTAA. If one strand of the double-stranded DNA is considered the sense strand, then the other strand, considered the antisense strand, will have the complementary sequence to the sense strand.
In the case of dried psilocybin-containing mushrooms, microdoses are 0.1 g to 0.3 g and psychedelic doses are 1.0 g to 3.5–5.0 g. The preceding 1.0 to 5.0 g range corresponds to psilocybin doses of about 10 to 50 mg. Psilocybin-containing mushrooms vary in their psilocybin and psilocin content, but are typically around 1% of the dried weight of the mushrooms (in terms of total or combined psilocybin and psilocin content). Psilocybin and psilocin are similar in potency and dose but psilocin is about 1.4-fold more active, this being related to the difference in molecular weight between the two compounds. Some psychedelics, such as 2C-B, 2C-E, 2C-P, methallylescaline (MAL), and 4-HO-DiPT among others, have been said to have steep dose–response curves, meaning that the difference in dose between a light experience and an overwhelming disconnection from reality can be small. Conversely, 2C-D is described as having an unusually wide and gradual dose range.
Sources: en.wikipedia.org
When Cooper boarded Faith 7 at 6:36 AM on the morning of May 14, he found a little gift that had been left for him. Alan Shepard, knowing that Cooper would have a new version of the urine containment device that Shepard did not have on his Mercury-Redstone 3 flight (forcing him to relieve himself during a long countdown hold), had left behind a suction-cup pump as a joke. Instructions on the handle said, "Remove Before Launch". The gift did not make the trip. Neither did Cooper that day. Various problems with radar in Bermuda and the diesel engine that rolled back the gantry caused the launch to be cancelled until May 15.
Stomach (when combined with gimeracil and oteracil) Breast (with uracil) Gallbladder Lung (specifically adenocarcinoma, typically with uracil) Colorectal (usually when combined with gimeracil and oteracil) Head and neck Liver (with uracil) Pancreatic It is often given in combination with drugs that alter its bioavailability and toxicity such as gimeracil, oteracil or uracil. These agents achieve this by inhibiting the enzyme dihydropyrimidine dehydrogenase (uracil/gimeracil) or orotate phosphoribosyltransferase (oteracil).
Immature seed pods, called "drumsticks" Leaves Mature seeds Oil pressed from seeds Flowers Roots Nutritional content of 100 g of fresh M. oleifera leaves (about 5 cups) is shown in the table (USDA data). The leaves are the most nutritious part of the plant, being a significant source of B vitamins, vitamin C, provitamin A as beta-carotene, vitamin K, manganese, and protein. Some of the calcium in moringa leaves is bound as crystals of calcium oxalate. Oxalate levels may vary from 430 to 1050 mg/100g, compared to the oxalate in spinach (average 750 mg/100g).
The vulva has a major role to play in the reproductive system. It provides entry to, and protection for the uterus, and the right conditions in terms of warmth and moisture that aids in its sexual and reproductive functions. The vulva is richly innervated and provides pleasure when properly stimulated. The mons pubis provides cushioning against the pubic bone during intercourse. A number of different secretions are associated with the vulva, including urine (from the urethral opening during urination through control of the external sphincter muscle), sweat (from the apocrine glands), menses (leaving from the vagina via the introitus), sebum (from the sebaceous glands), alkaline fluid (from the Bartholin's glands), mucus (from the Skene's glands), vaginal lubrication from the vaginal wall and smegma. Smegma is a white substance formed from a combination of dead cells, skin oils, moisture and naturally occurring bacteria, that forms in the genitalia. In females, this thickened secretion collects around the clitoris and labial folds. It can cause discomfort during sexual activity as it can cause the clitoral glans to stick to the hood, and is easily removed by bathing. Aliphatic acids known as copulins are also secreted in the vagina. These are believed to act as pheromones. Their fatty acid composition, and consequently their odor changes in relation to the stages of the menstrual cycle.
== Formation == The 82nd Division was constituted during World War I on 5 August 1917 as an infantry division in the National Army. It was organized and formally activated on 25 August 1917 at Camp Gordon, Georgia. At the time, the division consisted entirely of newly conscripted soldiers. Original enlisted men assigned to the division came from Alabama, Georgia, and Tennessee. In October 1917, nearly all of them were transferred to fill shortages in National Guard and National Army units, principally the 30th, 31st, and 81st Divisions, which were training at other camps in the Southern United States. Replacements for them were received mostly from Camp Devens, Massachusetts, Camp Dix, New Jersey, Camps Lee and Meade, Virginia, and Camp Upton, New York, the men hailing from New England and the Mid-Atlantic states. In the spring, 5,000 more replacements for transfers made over the winter were assigned from Fort Devens, Camp Gordon, Camp Upton, Camp Dodge, Iowa, and Camp Travis, Texas, along with a contingent of men from Alabama, Georgia, and Tennessee. The citizens of Atlanta held a contest to give a nickname to the new division. In April 1918, Major General Eben Swift, the commanding general, chose "All American" to reflect the unique composition of the 82nd—it had soldiers from all 48 states in the Union. The bulk of the division was two infantry brigades, each commanding two regiments. The 163rd Brigade commanded the 325th Infantry Regiment and the 326th Infantry Regiment along with the 320th Machine Gun Battalion.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.